Diligence memo · auto-generated · as of July 2, 2026
Inivata Ltd
Inivata Ltd looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Inivata Ltd operates in Biotechnology, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Inivata Ltd has raised $25M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $25M on 2020-05-22.
Most recent recorded round closed around 2020-05-22.
Valuation (modeled)modeled
Provath models Inivata Ltd at approximately $992M (range $50M–$3.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.61× the median modeled value of Series B Biotechnology companies in 2019–2021 (118 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 6.1 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 72% of Biotechnology peers (4293 compared).
Modeled value ranks above 89% of those peers.
Closest niche peers: Pandion Therapeutics Holdco LLC, Ocular Therapeutix, Inc, Insilico Medicine Cayman TopCo, Purigen Biosystems, Inc., Lucira Health, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.